Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

European Radiology

Volumn 16, Issue 11, 2006, Pages 2454-2462

  Vilana, R ^a,b   Bianchi, L ^a   Varela, M ^a   Nicolau, C ^a   Sanchez M ^a   Ayuso, C ^a   Garcia M ^a   Sala, M ^a   Llovet, J M ^a   Bruix, J ^a   Bru, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Department of Radiology CDIC ^*  (Spain)

Author keywords

Contrast enhanced ultrasound; Hepatocellular carcinoma; Percutaneous ethanol injection; Radiofrequency 3ablation; Spiral CT

Indexed keywords

ALCOHOL; SONOVUE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MICROBUBBLE; MINIMAL RESIDUAL DISEASE; PREDICTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ADMINISTRATION, CUTANEOUS; AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CENTRAL NERVOUS SYSTEM DEPRESSANTS; ETHANOL; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER NEOPLASMS; MALE; MICROBUBBLES; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SULFUR HEXAFLUORIDE; TIME FACTORS; TOMOGRAPHY, SPIRAL COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33750462798     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-006-0264-8     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156
2. Sangiovanni A, Del Ninno E, Fasani P et al (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4):1005-1014
3. Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: A prospective study on the incidence and hierarchy of major complications. Gut 53:744-749
4. Bruix J, Sherman M, Llovet JM et al (2001) Clinical Management of Hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35:421-430
5. Bartolozzi C, Lencioni R, Ricci P, Paolicchi A, Rossi P, Passariello R (1998) Hepatocellular carcinoma. Treatment with percutaneous ethanol injection. Evaluation with contrast enhanced color Doppler US. Radiology 209:387-393
6. Choi D, Lim HK, Kim SH et al (2000) Hepatocellular carcinoma treated with percutaneous radiofrequency ablation: Usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response. Preliminary results. Radiology 217:558-563
7. Ding H, Kudo M, Onda H, Suetomi Y, Minami Y, Maekawa K (2001) Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. AJR Am J Roentgenol 176:661-666
8. Meloni MF, Goldberg SN, Livraghi T et al (2001) Hepatocellular carcinoma treated with radiofrequency ablation: Comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am J Roentgenol 177:375-380
9. Cioni D, Lencioni R, Rossi S et al (2001) Radiofrequency thermal ablation of hepatocellular carcinoma: Using contrast-enhanced harmonic power Doppler sonography to assess treatment outcome. AJR Am J Roentgenol 177:783-788
10. Cedrone A, Pompili M, Sallustio G, Lorenzelli GP, Gasbarrini G, Rapaccini GL (2001) Comparison between color power Doppler ultrasound with echo-enhancer and spiral computed tomography in the evaluation of hepatocellular carcinoma vascularization before and after ablation procedures. Am J Gastroenterol 96:1854-1859
11. Choi D, Lim HK, Kim SH et al (2002) Assessment of therapeutic response in hepatocellular carcinoma treated with percutaneous radio frequency ablation: Comparison of multiphase helical computed tomography and power Doppler ultrasonography with a microbubble contrast agent. J Ultrasound Med 21:391-401
12. Numata K, Isozaki T, Ozawa Y, Sakaguchi T, Kiba T, Kubota T et al (2003) Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma. AJR Am J Roentgenol 180:143-149
13. Wen YL, Kudo M, Zheng RQ et al (2003) Radiofrequency ablation of hepatocellular carcinoma: Therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 181:57-63
14. Shimizu M, Iijima H, Horibe T et al (2004) Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent detection imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radio-frequency ablation therapy. Hepatol Res 29:235-242
15. Vilana R, Llovet JM, Bianchi L et al (2003) Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound 31:119-128
16. Schneider M, Arditi M, Barrau MB et al (1995) BR1: A new ultrasonographic contrast agent based on sulfur -hexafluoride- filled microbubbles. Invest Radiol 30:451-457
17. Morel DR, Schwieger I,Hohn L, Terrettaz J, Llull JB, Cornioley YA et al (2000) Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 35:80-85
18. Sala M, Llovet JM, Vilana R et al (2004) Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40:1352-1360
19. Wilson SR, Burns PN, Murdali D et al (2000) Harmonic hepatic US with microbubbles contrast agent: Initial experience showing improved characterisation of haemangioma, hepatocellular carcinoma and metastasis. Radiology 215:153-161
20. Leen E, Angerson WJ, Yarmenitis S et al (2002) Multi-centre clinical study evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 41:200-206
21. Basilico R, Blomley MJ, Harvey CJ et al (2002) Wich continuous US scanning mode is optimal for the detection of vascularity in liver lesions when enhanced with a second generation contrast agent? Eur J Radiol 41:184-191
22. Gaiani S, Celli N, Piscaglia F et al (2004) Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 41:421-426
23. Nicolau C, Catala V, Vilana R et al (2004) Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent. Correlation with cellular differentiation. Eur Radiol 14:1092-1099
24. von Hervay A, Vogt C, Willers R, Haussinger D (2004) Real-time imaging with the sonographic contrast agent SonoVue: Differentiation between benign and malignant hepatic lesions. J Ultrasound Med 23:1557-1568
25. Giorgio A, Ferraioli G, Tarantino L et al (2004) Contrast - enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: Comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol 183:1319-1326
26. Ricci P, laghi A, Cantisani V et al (2005) Contrast-enhanced sonography with SonoVue: Enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 184:821-827
27. Pasamonti M, Vercelli A, Azzaretti A, Rodolico G, Calliada F (2005) Characterización of focal liver lesions with a new ultrasound contrast agent using continuos low acoustic power imaging: Comparison with contrast enhanced spiral CT. Radiol Med 109:358-369
28. Bartolotta TV, Midiri M, Quaia E et al (2005) Benign focal liver lesions: Spectrum of findings on SonoVue-enhanced pulse-inversion ultrasonography. Eur Radiol 15:1643-1649
29. Krix M, Plathow C, Essig M et al (2005) Monitoring of liver metastases after stereotactic radiotherapy using low-MI contrast-enhanced ultrasound-initial results. Eur Radiol 15:677-684
30. Solbiati L, Ierace T, Tonolini M, Cova L (2004) Guidance and monitoring of radiofrequency liver tumor with contrast-enhanced ultrasound. Eur Radiol 51(Suppl):S19-S23
31. Solbiati L, Tonolini M, Cova L (2004) Monitoring RF ablation. Eur Radiol 14:34-42
32. Pompili M, Riccardi L, Covino M et al (2005) Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver international 25:954-961
33. Colagrande S, La Villa G, Batolucci M, Lanini F, Barletta G, Villari N (2003) Spiral computed tomography versus ultrasound in the follow-up of cirrhotic patients previously treated for hepatocellular carcinoma: A prospective study. J Hepatol 39:93-98